Traders bought shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Tuesday. $192.81 million flowed into the stock on the tick-up and $133.03 million flowed out of the stock on the tick-down, for a money net flow of $59.78 million into the stock. Of all companies tracked, Johnson & Johnson had the 7th highest net in-flow for the day. Johnson & Johnson traded down ($0.58) for the day and closed at $132.63

JNJ has been the topic of several research analyst reports. J P Morgan Chase & Co raised Johnson & Johnson from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $123.64 to $140.00 in a research report on Monday, May 15th. UBS AG reaffirmed a “buy” rating and set a $136.00 price target on shares of Johnson & Johnson in a research report on Monday, May 15th. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.82 price target on the stock. in a research report on Monday, May 15th. Stifel Nicolaus reaffirmed a “hold” rating and set a $128.00 price target (up previously from $124.00) on shares of Johnson & Johnson in a research report on Thursday, May 18th. Finally, Cowen and Company reaffirmed a “buy” rating and set a $143.00 price target (up previously from $138.00) on shares of Johnson & Johnson in a research report on Friday, May 19th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $134.60.

The firm’s 50 day moving average price is $132.42 and its 200-day moving average price is $128.96. The firm has a market cap of $355.98 billion, a PE ratio of 22.44 and a beta of 0.79.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same period in the prior year, the firm earned $1.74 EPS. The business’s quarterly revenue was up 1.9% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.53%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 56.76%.

In related news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Harding Loevner LP bought a new position in Johnson & Johnson in the 2nd quarter worth approximately $106,000. Lenox Wealth Advisors Inc. grew its holdings in Johnson & Johnson by 0.7% in the 1st quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after buying an additional 6 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares in the last quarter. IHT Wealth Management LLC grew its holdings in Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson in the 2nd quarter worth approximately $124,000. 66.00% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Traders Buy Johnson & Johnson (JNJ) on Weakness” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/12/traders-buy-johnson-johnson-jnj-on-weakness.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.